<DOC>
	<DOCNO>NCT00005801</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Peripheral stem cell transplantation may able replace immune cell destroy radiation therapy use kill tumor cell . Infusions donor white blood cell may decrease body 's rejection transplant peripheral stem cell . PURPOSE : Phase II trial study effectiveness combine radiation therapy , peripheral stem cell transplantation , donor white blood cell infusion treat old patient acute myeloid leukemia .</brief_summary>
	<brief_title>Total-Body Irradiation Plus Stem Cell Transplantation And White Blood Cell Infusion Treating Older Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether mixed full donor chimerism safely establish old patient acute myeloid leukemia ( AML ) treat nonmyeloablative conditioning comprise low dose total body irradiation , follow allogeneic peripheral blood stem cell transplantation , follow unrelated donor lymphocyte infusion ( DLI ) . II . Determine whether mixed chimerism safely convert full donor chimerism patient treat DLI . III . Determine potential efficacy regimen AML patient first remission . OUTLINE : Conditioning : Patients undergo low dose total body irradiation follow infusion allogeneic peripheral blood stem cell ( PBSC ) day 0 . Donor lymphocyte infusion : Nonmobilized donor lymphocyte harvest HLA identical related donor day 95 PBSC transplantation . Eligible patient mixed chimerism graft versus host disease ( GVHD ) receive first donor lymphocyte infusion ( DLI ) day donor lymphocyte collect . Patients continue mixed chimerism GVHD receive second DLI high dose level day 65 first DLI . Patients follow weekly day 90 , monthly thereafter . PROJECTED ACCRUAL : A total 40 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Acute myeloid leukemia ( AML ) ( de novo secondary , FAB M1 , M2 M47 ) Must within 6 month diagnosis Achieved chemotherapy induce first complete remission ( CR ) Received 1 course consolidation chemotherapy OR AML second great CR Patients document first subsequent CR may proceed transplantation : No morphologic diagnosis AML myelodysplastic syndrome Absolute neutrophil count great 1,000/mm3 platelet count great 50,000/mm3 consolidation chemotherapy Availability HLA identical related peripheral blood stem cell donor No syngeneic donor No active CNS leukemia PATIENT CHARACTERISTICS : Age : Over 55 75 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) ALT AST less 4 time ULN Renal : Creatinine clearance least 50 mL/min Cardiovascular : Cardiac ejection fraction least 40 % No poorly control hypertension Pulmonary : No severe defect pulmonary function test No requirement supplementary continuous oxygen PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>September 2001</verification_date>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
</DOC>